VimRx: FIPCO or Financier?
Executive Summary
VimRx's acquisition of Baxter's immunotherapy business is being touted by company officials as part of its transformation from a research-stage biotech to a fully integrated commercial enterprise. But others aren't so sure, saying the deal was driven more by Baxter's need to get the high R&D costs associated with its immunotherapy business off its books.